Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Company-reported prevalence

Emiltatug ledadotin

Overview

FieldValue
DrugEmiltatug ledadotin (Emi-Le and XMT-1660)
IndicationAdenoid cystic carcinoma with solid histology or high-grade transformation
DiseaseAdenoid cystic carcinoma (ACC), including adenoid cystic carcinoma type 1 (ACC-1)
CompanyServier (owner of Day One Biopharmaceuticals since April 2026); Day One Biopharmaceuticals, Inc. (global rights, through its acquisition of Mersana Therapeutics in January 2026); Mersana Therapeutics, Inc. (originator, now a subsidiary of Day One Biopharmaceuticals)
Documents searchedServier press releases dated May 12, 2026 and June 1, 2026; Servier corporate website home page (accessed October 2026); Day One Biopharmaceuticals website: home, pipeline, Emi-Le, and Emi-Le announcement pages (accessed October 2026); Day One Biopharmaceuticals press releases dated November 13, 2025 and January 6, 2026; Day One Biopharmaceuticals Form 10-K for 2025 (February 2026); Day One Biopharmaceuticals presentations: acquisition of Mersana Therapeutics (November 2025), J.P. Morgan Healthcare Conference (January 2026), fourth quarter 2025 results (February 2026), and corporate presentation (March 2026); Day One Biopharmaceuticals Schedule 14D-9 (April 2026); Mersana Therapeutics Form 10-K for 2024 (March 2025); Mersana Therapeutics Form 10-Q for the third quarter of 2025 (November 2025); Mersana Therapeutics press releases dated January 10, 2025 and June 2025; Mersana Therapeutics initial phase 1 data presentation (January 2025); Mersana Therapeutics ASCO 2025 presentation (access refused to scripted requests, October 2026); Mersana Therapeutics Schedule 14D-9 (December 2025); SEC full-text search of Day One Biopharmaceuticals and Mersana Therapeutics filings for "adenoid cystic carcinoma", "ACC-1", and "1,300 patients" (2025 to 2026)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Incidence: Day One Biopharmaceuticals corporate presentation, March 2026

“Annual U.S. incidence of” (opens the source at this quote in a new tab)

“~1,300 patients” (opens the source at this quote in a new tab)

Cited source: 2.1 Adenoid Cystic Carcinoma Research Foundation 2025

Day One Biopharmaceuticals (2026) corporate presentation, March 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

Number affected: Servier press release, June 2026

“Globally, more than 200,000 people have ACC.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Servier (2026) press release, June 1, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Other countries and regions

No evidence found.

Geography not stated

Incidence: Servier press release, June 2026

“It is diagnosed in roughly four per one million people annually, and does not discriminate by ethnicity or lifestyle factors.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Servier (2026) press release, June 1, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Prevalence (share of ACC with solid/basaloid or high-grade transformation histology): Day One Biopharmaceuticals Form 10-K for 2025, February 2026

“Up to 40% of patients have an aggressive form of ACC characterized by solid/basaloid or high-grade transformation histology and poor prognosis with median progression-free survival (PFS) of 2–3 months and median overall survival of approximately 3 years.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Day One Biopharmaceuticals (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Sources the company cites

Adenoid cystic carcinoma research foundation 2025

Reference as the company lists it

“Adenoid Cystic Carcinoma Research Foundation, includes both frontline and relapsed ACC.” (opens the source at this quote in a new tab)

Day One Biopharmaceuticals (2026) corporate presentation, March 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Passage carrying the figure

“ACC is diagnosed in 4 per million people each year (about 1,300 patients in the USA) and 33 per million people are living with an ACC diagnosis (about 11,000 patients in the USA). These incidence and prevalence rates are similar in Europe and Asia.” (opens the source at this quote in a new tab)

Adenoid Cystic Carcinoma Research Foundation (2025) Understanding ACC, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

References

  1. Adenoid Cystic Carcinoma Research Foundation (2025) Understanding ACC (opens in a new tab)
  2. Day One Biopharmaceuticals (2026) corporate presentation, March 2026 (opens in a new tab)
  3. Day One Biopharmaceuticals (2026) Form 10-K for 2025 (opens in a new tab)
  4. Servier (2026) press release, June 1, 2026 (opens in a new tab)